PTC Therapeutics starts phase 1a trial of PTC299 for oncology

By Elaine Rigoli

Tampa, Fla., May 12 - PTC Therapeutics, Inc. has started a phase 1a single-site, randomized, double-blind, placebo-controlled escalating single-dose safety and pharmacokinetic study of PTC299 in healthy volunteers in Belgium.

The primary objective of this trial is to determine a dose range for PTC299 that is well tolerated, achieves pharmacologically active plasma concentrations and is appropriate for use in a subsequent phase 1b multiple-dose study, according to a news release.

PTC expects to complete this trial in the second quarter of 2006.

If this trial is successful, PTC plans to initiate further clinical trials of PTC299 in solid tumor cancer patients, the release said.

South Plainfield, N.J.-based PTC is a biopharmaceutical company focused on the development of small-molecule drugs that target post-transcriptional control processes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.